Role of sex hormones in modulating breast and ovarian cancer associated pain

Mol Cell Endocrinol. 2021 Aug 1:533:111320. doi: 10.1016/j.mce.2021.111320. Epub 2021 May 24.

Abstract

According to the National Cancer Institute in 2020 there will be an estimated 21,750 new ovarian cancer cases and 276,480 new breast cancer cases. Both breast and ovarian cancer are hormone dependent cancers, meaning they cannot grow without the presence of hormones. The two most studied hormones in these two cancers are estrogen and progesterone, which are also involved in the modulation of pain. The incidence of pain in breast and ovarian cancer is very high. Research about mechanisms involved in modulation of pain by hormones are still being debated, as some studies find estrogen to be anti-nociceptive and others pro-nociceptive in pain studies. Moreover, analgesic treatments for breast and ovarian cancer-associated pain are limited and often ineffective. In this review, we will focus on estrogen and progesterone mechanisms of action in modulation of pain and cancer. We will also discuss new treatment options for these types of cancer and associated-pain.

Keywords: Breast; Cancer; Cannabinoids; Estrogen; Ovarian; Pain; Progesterone.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / therapeutic use
  • Breast Neoplasms / complications*
  • Breast Neoplasms / metabolism
  • Cancer Pain / drug therapy
  • Cancer Pain / epidemiology
  • Cancer Pain / metabolism*
  • Estrogens / metabolism*
  • Female
  • Humans
  • Incidence
  • Molecular Targeted Therapy
  • Ovarian Neoplasms / complications*
  • Ovarian Neoplasms / metabolism
  • Progesterone / metabolism*

Substances

  • Analgesics
  • Estrogens
  • Progesterone